Periphagen is a biopharmaceutical company focused on peripheral nerve gene therapy for disorders such as neuropathy and chronic pain. It provides a Neuronal Therapeutics (NET) platform expressing gene constructs in discrete regions of the nervous system. The company also offers PGN-503, a compound against Chemotherapy Induced Peripheral Neuropathy (CIPN).